Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
Diabetes, Obesity and Metabolism · 2026-03 · 28 (3) · 2403-2415
DOI: 10.1111/dom.70436 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.01.2026. Verfasst von Lauren Wilson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk, Inc., Plainsboro, New Jersey, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Cardiovascular Diseases, Overweight. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk, Inc..
Abstract (Originalsprache)
Aims
To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population. Materials and Methods This retrospective, observational cohort study used Komodo Research Data and included patients ≥45 years of age with overweight/obesity and ≥1 claim for myocardial infarction (MI), ischemic stroke, or peripheral artery disease first treated with semaglutide or tirzepatide between 13/5/2022–31/1/2025. Propensity score matching was used to balance key baseline characteristics between cohorts. Primary outcomes included revised 3‐point MACE (rMACE‐3: MI, stroke, all‐cause mortality) and revised 5‐point MACE (rMACE‐5: rMACE‐3, coronary revascularization, hospitalisation for heart failure). Cox proportional hazard models were used to compare time to first event for study outcomes. A secondary per‐protocol analysis was conducted where patients were censored at treatment discontinuation (gap in therapy >30 days).
Results
10 625 patients were included in each matched cohort. Semaglutide was associated with statistically significant 29% (hazard ratio [HR] 0.71; p = 0.046) and 22% (HR 0.78; p = 0.040) reductions in the risk of rMACE‐3 and rMACE‐5, respectively, compared with tirzepatide. In the per‐protocol analysis, semaglutide continued to be associated with a significantly lower risk of rMACE‐3 (HR 0.43; p = 0.005) and rMACE‐5 (HR 0.57; p = 0.003) compared with tirzepatide.
Conclusions
This real‐world analysis of a large US claims database shows semaglutide was associated with early and significantly greater reductions in the risk of rMACE‐3 and rMACE‐5 versus tirzepatide among patients with overweight or obesity and ASCVD but without diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk, Inc., Plainsboro, New Jersey, USA.
- Novo Nordisk A/S, Søborg, Denmark.
Förderung
- Novo Nordisk, Inc.
Zitieren
APA
Wilson, L., Zhao, Z., Divino, V., Bassan, M., Hartaigh, B. Ó., Stensen, S., & Ozer, K. (2026). Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ). Diabetes, Obesity and Metabolism, 28(3), 2403-2415. https://doi.org/10.1111/dom.70436
Vancouver
Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ). Diabetes, Obesity and Metabolism. 2026;28(3):2403-2415. doi:10.1111/dom.70436
BibTeX
@article{Wilson2026,
author = {Wilson, Lauren and Zhao, Zhenxiang and Divino, Victoria and Bassan, Matthew and Hartaigh, Bríain Ó and Stensen, Signe and Ozer, Kerem},
title = {Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {3},
pages = {2403--2415},
doi = {10.1111/dom.70436}
}
EUVIMED